Medical and Health News - MediPaper Medical Communications Ltd.

Breast-Cancer-Update-2021

1st February 2021

Breast cancer update January 2021

With the San Antonio Breast Cancer Conference (SABCS) 2020 by AACR just completed, several new and clinical relevant phase 2 and phase 3 have been published in the Journal of the American Medical Association, Clinical Cancer Research, New England Journal of Medicine, Journal of Clinical Oncology, and Lancet Oncology. ['mediPr] provides you with an overview.

Osimertinib approved as the first adjuvant treatment for early non-small cell lung cancer

28th January 2021

Osimertinib approved as the first adjuvant treatment for early non-small cell lung cancer

Increasing dose frequency of lanreotide autogel injections in neuroendocrine tumours

27th January 2021

Increasing dose frequency of lanreotide autogel injections in neuroendocrine tumours

U.S. FDA approved immunecheckpoint inhibitors U.S. FDA approved immunotherapies for cancer U.S. FDA approved immunotherapies for cancer

8th December 2020

US FDA approved immune-checkpoint inhibitors updated 08-Dec-2020

detecting metastases with psma pet in prostate cancer

8th December 2020

Detecting metastases with PSMA-PET in prostate cancer

asco guidelines for the use of systemic therapies in advanced hepatocellular cancer

7th December 2020

ASCO Guidelines for the Use of Systemic Therapies in Advanced Hepatocellular Cancer

Sotorasib for the treatment of KRASG12C-mutated lung cancer

15th October 2020

Sotorasib for the treatment of KRASG12C mutated lung cancer

Capmatinib therapy for the treatment of MET-positive non-small cell lung cancer

15th October 2020

Capmatinib therapy for the treatment of MET-positive non-small cell lung cancer

ESMO-releases-the-first-guideline-on-NGS-testing- in-cancers

7th September 2020

ESMO releases the first guideline on NGS testing in cancers

residual-risk-of-hepatocellular-carcinoma-in-older-hepatitis-c-patients-even-after-viral-clearance

13th August 2020

Residual risk of hepatocellular carcinoma in older Hepatitis C patients even after viral clearance

detecting metastases with psma pet in prostate cancer

8th December 2020

Detecting metastases with PSMA-PET in prostate cancer

Conventional imaging with computed tomography (CT), magnetic resonance imaging (MRI) and bone scans, are the current standard of care for imaging prostate cancer. Accurate imaging primarily relies on nodal metastases size for detection.

residual-risk-of-hepatocellular-carcinoma-in-older-hepatitis-c-patients-even-after-viral-clearance

13th August 2020

Residual risk of hepatocellular carcinoma in older Hepatitis C patients even after viral clearance

updated-human-papillomavirus-vaccination-and-testing-recommendations-from-the-american-cancer-society

13th August 2020

Updated human papillomavirus vaccination and testing recommendations from the American Cancer Society

Carboplatin plus paclitaxel to be the new standard of care for anal cancer

10th July 2020

Carboplatin plus paclitaxel to be the new standard of care for anal cancer

ASCO 2020 ASCO20 virtual meeting NSCLC SCLC lung cancer breast cancer hepatocellular cancer HCC colorectal cancer CRC

30th June 2020

ASCO 2020 Lung, Breast, and Liver Cancer Update

Toxic vaccine disinformation_有關疫苗的虛假信息

11th January 2021

有關疫苗的虛假信息

我最近在YouTube頻道上看到這條在2020年12月17日發佈的視頻，聲稱說明有關COVID-19疫苗的功效和風險。該視頻的內容非常不準確且具有誤導性。令我震驚的是，該視頻已吸引了超過三十萬觀看者，其中有幾位評論者表示同意偽科學。

Patient Blood Management and Treatment of iron Deficiency Anaemia in Gynaecological Conditions

23rd December 2020

Patient Blood Management and Treatment of iron Deficiency Anaemia in Gynaecological Conditions

data-for-safe-and-effective-use-of-evolocumab-in-paediatric-familial-hypercholesterolaemia

8th October 2020

Data for safe and effective use of evolocumab in paediatric familial hypercholesterolaemia

psoriasis-biologics-may-help-reduce-coronary-plaque

8th October 2020

Psoriasis biologics may help reduce coronary plaque

ticagrelor-may-not-confer-post-mi-benefits-to-elderly-patients

8th October 2020

Ticagrelor may not confer post-MI benefits to elderly patients

Evidence-of-SARS-CoV2-in-heart-cells

22nd September 2020

Evidence of SARS-CoV2 in heart cells

triple-combination-effective-for-hospital-and-ventilator-acquired-pneumonia

10th September 2020

Triple combination effective for hospital- and ventilator-acquired pneumonia

Selpercatinib-displays-efficacy-in-RET -fusion-positive-non-small-cell-lung-cancer

7th September 2020

Selpercatinib displays efficacy in RET fusion-positive non-small cell lung cancer

7th September 2020

First liquid biopsy for NSCLC to receive FDA approval

risk-of-thrombosis-with-sars-cov-2-infection

27th August 2020

Risk of thrombosis with SARS-CoV-2 infection

CANCERINFORMER

腫瘤學新知 Cancer Informer 癌症資訊癌症治療癌症腫瘤確診患癌究竟甚麼是癌癌症怎樣醫

MediPaper Medical Communications Ltd

BREAKING

Dr Sridhar Siddharth - Clinical characteristics of patients with 2019-nCoV pneumonia WARS Wuhan Pneumonia coronavirus outbreak sars mers COVID-19 2019-nCoV WuhanOutbreak Pneumonia

MediPaper Medical Communications Ltd

irAE immune-related adverse events immune-mediated adverse events hepatitis pneumonitis rash diabetes_small

©invincible7 / 123RF Stock Photo

CONFERENCE HIGHLIGHTS

ESMO-2018-ESMO18-pembrolizumab-nivolumab-durvalumab-atezolizumab-avelumab-ipilimumab-tremelimumab-osimertinib-cabozantinib-lenvatinib-lorlatinib

©European Society for Medical Oncology

ECTRIMS2018 multiple sclerosis MS neurology

©ECTRIMS

ASCO 2018 ASCO18 pembrolizumab nivolumab durvalumab atezolizumab avelumab ipilimumab tremelimumab olaparib rucaparib niraparib PARP palbociclib ribociclib abemaciclib CDK46 osimertinib cabozantinib lenvatinib lorlatinib

©American Society for Clinical Oncology (ASCO)

aacr2018 american association for cancer research annual meeting 2018 AACR 2018 AACR annual meeting 2018

©American Association for Cancer Research

CSA2017-0-中华医学会第25-次全国麻醉学术年会-2017-郑州-25th-Annual-Meeting-of-the-Chinese-Society-of-Anaesthesiology

©Chinese Society for Anesthesiology

esmo 2016

© European Society for Medical Oncology

Therapeutic Areas

Therapeutic Areas

ONCOLOGY ARTICLES

Breast-Cancer-Update-2021

1st February 2021

Breast cancer update January 2021

With the San Antonio Breast Cancer Conference (SABCS) 2020 by AACR just completed, several new and clinical relevant phase 2 and phase 3 have been published in the Journal of the American Medical Association, Clinical Cancer Research, New England Journal of Medicine, Journal of Clinical Oncology, and Lancet Oncology. ['mediPr] provides you with an overview.

Osimertinib approved as the first adjuvant treatment for early non-small cell lung cancer

28th January 2021

Osimertinib approved as the first adjuvant treatment for early non-small cell lung cancer

Increasing dose frequency of lanreotide autogel injections in neuroendocrine tumours

27th January 2021

Increasing dose frequency of lanreotide autogel injections in neuroendocrine tumours

U.S. FDA approved immunecheckpoint inhibitors U.S. FDA approved immunotherapies for cancer U.S. FDA approved immunotherapies for cancer

8th December 2020

US FDA approved immune-checkpoint inhibitors updated 08-Dec-2020

detecting metastases with psma pet in prostate cancer

8th December 2020

Detecting metastases with PSMA-PET in prostate cancer

cancer informer 腫瘤學新知分享腫瘤領域最新進展包含熱議話題、專題和實用工具例如 NCCN ASCO 及 ESMO 消息更新

MediPaper Medical Communications Ltd

Dr Sridhar Siddharth - Clinical characteristics of patients with 2019-nCoV pneumonia WARS Wuhan Pneumonia coronavirus outbreak sars mers COVID-19 2019-nCoV WuhanOutbreak Pneumonia

MediPaper Medical Communications Ltd

irAE immune-related adverse events immune-mediated adverse events hepatitis pneumonitis rash diabetes_small

©invincible7 / 123RF Stock Photo

[the_ad id=”45772″]

ONCOLOGY ARTICLES (Cont’d)

Lower-risk-MDS-patients-benefit-from-novel-drug-imetelstat

10th July 2020

Lower-risk MDS patients benefit from novel drug, imetelstat

Myelodysplastic syndromes (MDS) are a heterogenous group of clonal haematopoietic disorders that carry a risk of progression to acute myeloid leukaemia (AML). Patients are stratified into risk groups due to the heterogeneity of the disease, which is also exemplified by median overall survival (OS) of 8.8 years for very low risk, and 0.8 years for very high risk patients. Due to symptoms such as anaemia, supportive red blood cell (RBC) transfusions are needed in 80-90% of patients during their disease course, although RBC dependence has been shown to be an adverse prognostic marker.

Gastric Cancer ramucirumab cyramza pembrolizumab keytruda trastuzumab herceptin dMMR MSI HER2 VEGF VEGFR gastric adenocarcinoma GEJ gastroesophageal junction cancer

30th April 2020

Second-line treatment of gastric cancer or cancer of the gastroesophegeal junction: a case study of ramucirumab in Hong Kong

Capivasertib added to fulvestrant improves progression-free survival in advanced breast cancer patients

19th February 2020

Capivasertib added to fulvestrant improves progression-free survival in advanced breast cancer patients

Capivasertib combined with paclitaxel improves survival of metastatic triple-negative breast cancer patients

11th February 2020

Capivasertib plus paclitaxel improves survival of metastatic triple-negative breast cancer patients

Olaparib plus Bevacizumab as Maintenance Therapy in Ovarian Cancer

24th January 2020

Olaparib plus Bevacizumab as Maintenance Therapy in Ovarian Cancer

ADDING RIBOCICLIB TO FULVESTRANT IMPROVES THE SURVIVAL OF ADVANCED BREAST CANCER PATIENTS MONALEESA-3

12th January 2020

Ribociclib plus Fulvestrant Improves Survival in Advanced Breast Cancer

ASCO 2019 lung cancer NSCLC ASCO19 SCLC mesothelioma KEYNOTE-189 KEYNOTE-001 IMpower150 MYSTIC LCMC3 Lung-MAP S1400G S1400I Flaura CALGB 30901 DETERRED COMPASS

12th June 2019

ASCO 2019 Lung Cancer: 36 Oral Presentations of the ASCO19 lung cancer track summarised

paclitaxel, cobimetinib, Cotellic, MEK, Exelixis, atezolizumab, Tecentriq, nab-paclitaxel pembrolizumab, Keytruda, Merck, MSD, eribulin mesylate, Halaven, pertuzumab, trastuzumab, Herceptin, Perjeta, docetaxel, Taxotere, Sanofi, trastuzumab-dkst, Ogivri, Mylan, Biocon, margetuximab, MacroGenics, capecitabine, Xeloda, Genentech, gemcitabine, Gemzar, vinolrebine, pyrotinib, Jiangsu HengRui Medicine, neratinib, Nerlynx, Puma, lapatinib, Tykerb, carboplatin, T-DM1, ado-trastuzumab emtansine, Kadcyla doxorubicin, cisplatin, olaparib, Lynparza, cyclophosphamide, epirubicin, Ellence, Pharmorubicin, letrozole, Femara, Novartis, AI, NSAI, capivasertib, capivasertib, AZD5363, AKT, hormonal therapy, endocrine therapy, CDK4/6, RAD001, mTOR, fulvestrant, Faslodex, abemaciclib, Verzenio, Eli Lilly, ribociclib, Kisqali, goserilin, Zoladex, AstraZeneca, everolimus, Afinitor, exemestane, Aromasin, Pfizer, palbociclib, Ibrance, #ASCO2019, AKT1, AZ, BRCA, chemotherapy, CNS metastases, ER-positive, ESR1, GnRH, HER2-negative, HER2-positive, HR-positive, LABC, neoadjuvant, OfS, PARP, PARPi, pCR, PD-L1, postmenopausal, PR-positive, premenopausal, RB1, TAC, taxane, TNBC, trastuzumab, triptorelin

3rd June 2019

ASCO 2019 Breast Cancer: The ASCO19 breast cancer track summarised

KEYNOTE-158 pembrolizumab in previously treated advanced cervical cancer

24th April 2019

KEYNOTE-158: pembrolizumab in previously treated advanced cervical cancer

Atezolizumab with or without cobimetinib vs regorafenib for previously treated metastatic colorectal cancer IMblaze370

22nd April 2019

Atezolizumab +/- cobimetinib vs regorafenib for previously treated metastatic colorectal cancer (IMblaze370)

ESMO-2018-ESMO18-pembrolizumab-nivolumab-durvalumab-atezolizumab-avelumab-ipilimumab-tremelimumab-osimertinib-cabozantinib-lenvatinib-lorlatinib

©European Society for Medical Oncology

ECTRIMS2018 multiple sclerosis MS neurology

©ECTRIMS

ASCO 2018 ASCO18 pembrolizumab nivolumab durvalumab atezolizumab avelumab ipilimumab tremelimumab olaparib rucaparib niraparib PARP palbociclib ribociclib abemaciclib CDK46 osimertinib cabozantinib lenvatinib lorlatinib

©American Society for Clinical Oncology (ASCO)

[the_ad id=”45772″]

further-analyses-of-dapa-hf-shows-dapagliflozin-leads-to-fewer-outpatient-heart-failure

25th August 2020

Class effect of SGLT2 inhibitors on heart failure reduction solidified with dapagliflozin and empagliflozin results

Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been used in the treatment of type 2 diabetes mellitus (T2DM) to inhibit renal glucose reabsorption and thereby increase urinary glucose loss.

potential-protective-effects-of-the-influenza-vaccine-on-cardiovascular-outcomes-in-high-risk-populations

13th August 2020

Potential protective effects of the influenza vaccine on cardiovascular outcomes in high-risk populations

Dr Sridhar Siddharth - Clinical characteristics of patients with 2019-nCoV pneumonia COVID-19 2019-nCoV WuhanOutbreak Pneumonia

26th February 2020

Updated: Clinical characteristics of patients with COVID-19

Dr Siddharth Sridhar - 2019-nCoV COVID-19 in Hong Kong - the end of the beginning

22nd February 2020

COVID-19 in Hong Kong: the end of the beginning?

Dr Siddharth Sridhar - 2019-nCoV COVID-19 - How do People get Covid-19 in Hong Kong 在本港，人們如何感染Covid-19

20th February 2020

How do people get COVID-19 in Hong Kong

Dr Siddharth Sridhar - 2019-nCoV - Summary of the situation in HK 2019-nCoV在本港的概況 COVID-19 2019-nCoV WuhanOutbreak Pneumonia

7th February 2020

2019-nCoV – Summary of the situation in HK as of Feb 6, 2020

Dr Sridhar Siddharth - How infectious is novel coronavirus 2019 nCoV 新型冠狀病毒 2019-nCoV 的傳染性有多高 COVID-19 2019-nCoV WuhanOutbreak Pneumonia

3rd February 2020

How infectious is novel coronavirus (2019-nCoV)

Dr Siddharth Sridhar - How stable are coronaviruses in the environment? 2019-nCoV 冠狀病毒在環境中的穩定性 COVID-19 2019-nCoV WuhanOutbreak Pneumonia

2nd February 2020

2019-nCoV: how stable are coronaviruses in the environment?

Dr Sridhar Siddharth - Who gets severe novel coronavirus (2019-nCoV) infection COVID-19 2019-nCoV WuhanOutbreak Pneumonia

1st February 2020

Who gets severe novel coronavirus (2019-nCoV) infection?

Somazina citicoline small vessel disease vascular cognitive impairment traumatic brain injury neuroimaging cerebrovascular disorders ischaemic haemorraghic stroke rehabilitation neuroprotection

16th December 2019

Highlights of the 8th Asia Pacific Symposium on Cerebrovascular Disease

aacr2018 american association for cancer research annual meeting 2018 AACR 2018 AACR annual meeting 2018

©American Association for Cancer Research

CSA2017-0-中华医学会第25-次全国麻醉学术年会-2017-郑州-25th-Annual-Meeting-of-the-Chinese-Society-of-Anaesthesiology

©Chinese Society for Anesthesiology

esmo 2016

© European Society for Medical Oncology

MediPaper Medical Communications Agency Hong Kong Blog

MediPaper Medical Communications Agency Hong Kong Blog